Circulating
biomarkers have become a promising modality in the management of many cancers.
Similarly, in breast cancer, circulatory biomarkers are useful, non-invasive
methods in the diagnosis, prognostication, and evaluation of response to
treatment. Invasive surgical biopsies can be potentially replaced by “liquid biopsy,”
which involves analysing circulatory biomarkers that may reveal features of primary
and metastatic disease. Therefore, providing an insight into the cancer biology
can be utilised to monitor treatment response, treatment-induced adaptation and
tumour and disease progression through non-invasive means. The objective of
this review is to provide an overview of the current status of the circulating
biomarkers highlighting their promising impact on the management of patients
with breast cancer.
Keywords: Biomarkers, Breast cancer, Circulatory biomarkers, Diagnosis, Prognostication, Liquid biopsy.
